Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension.

Zhou, Yu-Ping, Wei, Yun-Peng, Yang, Yin-Jian, Xu, Xi-Qi, Wu, Tao, Liu, Chao, Mei, Ke-Yi, Peng, Fu-Hua, Wang, Hai-Ping, Sun, Kai, Li, Jing-Yi, Wang, Hui-Fang, Li, Meng-Tao, Wang, Duolao ORCID: https://orcid.org/0000-0003-2788-2464, Miao, Qi, Jiang, Xin and Jing, Zhi-Cheng (2022) 'Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension.'. Journal of the American College of Cardiology, Vol 79, Issue 15, pp. 1477-1488.

Preview

Text JACC110321-4192NR-Manuscript.pdf - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (356kB) | Preview

Abstract

Percutaneous transluminal pulmonary angioplasty (PTPA) is a treatment modality for chronic thromboembolic pulmonary hypertension, but whether it can be applied to Takayasu arteritis-associated pulmonary hypertension (TA-PH), another chronic obstructive pulmonary vascular disease, remains unclear. This study sought to investigate the efficacy and safety of PTPA for TA-PH. Between January 1, 2016, and December 31, 2019, a total of 50 patients with TA-PH who completed the PTPA procedure (the PTPA group) and 21 patients who refused the PTPA procedure (the non-PTPA group) were prospectively enrolled in this cohort study. The primary outcome was all-cause mortality. The safety outcomes included PTPA procedure-related complications. Baseline characteristics and medical therapies were similar between the PTPA group and the non-PTPA group. During a mean follow-up time of 37 ± 14 months, deaths occurred in 3 patients (6.0%) in the PTPA group and 6 patients (28.6%) in the non-PTPA group, contributing to the 3-year survival rate of 93.7% in the PTPA group and 76.2% in the non-PTPA group (P = 0.0096 for log-rank test). The Cox regression model showed that PTPA was associated with a significantly reduced hazard of all-cause mortality in TA-PH patients (HR: 0.18; 95% CI: 0.05-0.73; P = 0.017). No periprocedural death occurred. Severe complications requiring noninvasive positive pressure ventilation occurred in only 1 of 150 total sessions (0.7%). PTPA tended to be associated with a reduced risk of all-cause mortality with acceptable safety profiles and seemed to be a promising therapeutic option for TA-PH patients.

Item Type:	Article
Subjects:	WG Cardiovascular System > WG 20 Research (General) WG Cardiovascular System > Heart. Heart Diseases > WG 200 General works
Faculty: Department:	Clinical Sciences & International Health > Clinical Sciences Department
Digital Object Identifer (DOI):	https://doi.org/10.1016/j.jacc.2022.01.052
SWORD Depositor:	JISC Pubrouter
Depositing User:	JISC Pubrouter
Date Deposited:	22 Sep 2022 11:49
Last Modified:	23 Aug 2023 14:17
URI:	https://archive.lstmed.ac.uk/id/eprint/20335

Statistics

View details

Actions (login required)

Edit Item